{"schema_version":"secwatch.filing_event.v1","accession":"0001100682-25-000019","form_type":"8-K","ticker":"CRL","cik":"0001100682","company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.521242+00:00","generated_at":"2026-05-22T06:56:46.934302+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Charles River Q1 revenue down 2.7% to $984.2M; raises FY2025 guidance","bullets":["GAAP EPS $0.50 vs $1.30 YoY; Non-GAAP EPS $2.34 vs $2.27, up 3.1%.","Revenue decline across all segments: RMS -3.5%, DSA -2.1%, Manufacturing -3.6%.","DSA net bookings reached highest level in two years, signaling demand stabilization.","Raised FY2025 Non-GAAP EPS guidance to $9.30-$9.80 from $9.10-$9.60; organic revenue growth range narrowed.","Repurchased $350M of common stock in Q1; $549.3M remaining on $1B authorization."],"urls":{"canonical":"https://secwatch.observer/filing/0001100682-25-000019","json":"https://secwatch.observer/filing/0001100682-25-000019.json","markdown":"https://secwatch.observer/filing/0001100682-25-000019.md","text":"https://secwatch.observer/filing/0001100682-25-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1100682/000110068225000019/0001100682-25-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1100682/000110068225000019/crl-20250507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T06:56:46.934302+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}